{"id":"valsartan-atenolol","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL24","moleculeType":"Small molecule","molecularWeight":"266.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Atenolol is a beta-1 selective adrenergic antagonist that decreases heart rate and cardiac contractility. Together, these complementary mechanisms provide synergistic blood pressure reduction.","oneSentence":"This combination drug lowers blood pressure by blocking angiotensin II receptors (valsartan) and beta-adrenergic receptors (atenolol) to reduce vasoconstriction and heart rate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:52.923Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT01904981","phase":"PHASE4","title":"Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-01","conditions":"Small Abdominal Aortic Aneurysm","enrollment":19},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT00171756","phase":"PHASE4","title":"Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-06","conditions":"Hypertension","enrollment":92},{"nctId":"NCT00171132","phase":"PHASE4","title":"VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-08","conditions":"Hypertension","enrollment":64},{"nctId":"NCT02403349","phase":"PHASE4","title":"Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2012-05","conditions":"Blood Pressure, Ischemic Stroke","enrollment":105},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99},{"nctId":"NCT00396656","phase":"PHASE3","title":"Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Hypertension","enrollment":30},{"nctId":"NCT00687973","phase":"PHASE4","title":"Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-01","conditions":"Hypertension","enrollment":393},{"nctId":"NCT00295542","phase":"PHASE4","title":"Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2000-03","conditions":"Hypertension","enrollment":3344},{"nctId":"NCT00310778","phase":"PHASE1","title":"Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-03","conditions":"Healthy","enrollment":64},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"valsartan/atenolol","genericName":"valsartan/atenolol","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug lowers blood pressure by blocking angiotensin II receptors (valsartan) and beta-adrenergic receptors (atenolol) to reduce vasoconstriction and heart rate. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}